ALMS

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Drappa JornChief Medical Officer --11.3k shares Grant / ExerciseMay 22, 2026 $100.0K11.3k shares $8.84 $21.16
Drappa JornChief Medical Officer --15.5k shares Grant / ExerciseMay 22, 2026 $78.6K15.5k shares $5.06 $21.16

News

fool.comThis Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarterfool.comMay 24

fool.comAlumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarterfool.comMay 17

fool.comAlumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Backfool.comMay 15

globenewswire.comAlumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievementsglobenewswire.comMay 14

fool.comWhy One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drugfool.comMay 10

Trade ALMS

About Alumis Inc. Common Stock

Alumis Inc. is a biopharmaceutical firm currently in the clinical trial phase, dedicated to advancing and marketing therapeutic solutions for a range of autoimmune conditions. Its pipeline includes ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor, which is being investigated for its potential in addressing plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Another key candidate is A-005, also an allosteric TYK2 inhibitor, specifically designed to penetrate the central nervous system to target neuroinflammatory and neurodegenerative disorders. Originally established as Esker Therapeutics, Inc., the organization rebranded as Alumis Inc. in January 2022. Founded in 2021, Alumis maintains its corporate headquarters in South San Francisco, California.

CEO: Martin Babler
IPO Date: Feb 22, 2021

Market Data

Open: $20.26
High: $21.00
Low: $19.04
Volume: 1.4M
52W High: $30.60
52W Low: $2.76

Valuation

Market Cap: $2.4B
Enterprise Value: $2.3B

Financials

Free Cash Flow: $-370M
Revenue: $24M
Net Income: $-243M
Cash: $90M
Debt: $37M

Events

EarningsAug 12

EPS est. -0.7